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Abstract
The role of ezetimibe in lowering plasma cholesterol has
been established; however, controversy remains about its
clinical benefit. A recent study utilizes naturally occurring
genetic variation within the NPC1-like 1 gene (NPC1L1) to
demonstrate the potential for pharmacologic inhibition
of the protein to reduce the risk of coronary heart
disease. This research demonstrates the application
of the concept of genocopy to a population-based
validation of NPC1L1 as a therapeutic target.
Ezetimibe as an adjunct to statin therapy in
cardiovascular disease
Cardiovascular diseases (CVDs) are the primary cause of
death globally [1]. In 2008, 30% of all global deaths were
attributed to CVDs, including an estimated 7.3 million
deaths caused by coronary heart disease (CHD) [1]. As
a major risk factor for CHD, increased circulating chol-
esterol - particularly low-density lipoprotein choles-
terol (LDL-C) - is a well-established target for clinical
intervention. Although treatment with 3-hydroxy-3-
methyl-glutaryl-CoA reductase (HMGCR) inhibitors
(statins) has been shown both to lower LDL-C levels and
to reduce major cardiovascular events, in some cases sta-
tin therapy alone is insufficient to achieve optimal LDL-C
levels [2]. Currently, ezetimibe, which inhibits the function
of the NPC1L1 protein, can be prescribed alongside sta-
tins in order to achieve further reductions in LDL-C or as
an alternative in instances where statins are contraindi-
cated. Whilst the ability of ezetimibe to independently and
additively lower LDL-C beyond the levels achieved by
statins alone does not appear to be in question, the degree
to which the drug contributes to a reduction in the risk of
clinically relevant cardiovascular outcomes such as CHD
is unclear.
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Numerous trials have been conducted to assess the
clinical utility of LDL-C-lowering therapies in reducing
the incidence of CVD. The Pravastatin or Atorvastatin
Evaluation and Infection Therapy Trial (PROVE-IT)
demonstrated that more intensive lipid lowering achieved
through an increased statin dose clinically benefited pa-
tients who had previously suffered an acute coronary syn-
drome [3]. However, whether the same benefits can be
achieved by prescribing ezetimibe alongside statins to
achieve similar reductions in LDL-C remains uncertain
owing to inconsistent trial outcomes, particularly where
endpoints such as carotid intimal thickening and vascular
reactivity have been used as surrogates for CVD risk [2].
Two of the largest randomized control trials (RCTs)
designed to determine whether adding ezetimibe to statins
provides clinical benefit (over and above statin monother-
apy) carried out to date are the Ezetimibe and Simvastatin
in Hypercholesterolemia Enhances Atherosclerosis Regres-
sion (ENHANCE) trial and IMProved Reduction of Out-
comes: Vytorin Efficacy International Trial (IMPROVE-IT).
The ENHANCE trial (in which patients with heterozygous
familial hypercholesterolemia received simvastatin with or
without ezetimibe) was designed to study the effect of ezeti-
mibe on the progression of atherosclerosis, using carotid
intima-media thickness (IMT) as a target endpoint. In this
trial, the addition of ezetimibe to simvastatin therapy in the
treatment of familial hypercholesterolemia did not produce
a reduction in carotid IMT, despite achieving a differential
reduction in LDL-C [4]. This result was contrary to findings
of similar trials conducted around the same time [2]. In
November 2014, preliminary results of the landmark
IMPROVE-IT, designed to determine whether adding eze-
timibe to simvastatin in patients presenting with acute
coronary syndromes adds clinical benefit by further redu-
cing major cardiovascular events compared with simva-
statin monotherapy [5], were presented at the American
Heart Association Annual Meeting (Chicago, IL, Nov.
15-19, 2014). Although a full description of the findings
is yet to be published, preliminary results apparently
suggest a modest benefit in reducing cardiovascular events
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with the addition of ezetimibe to simvastatin in this
population of around 18,000 patients from 39 countries.
However, overall, the discordant results of studies carried
out to date has generated a degree of scepticism about
whether ezetimibe offers any health benefits above and be-
yond those afforded by statin therapy.
Using a population-based approach theoretically derived
from the concept of genocopy, Stitziel et al. [6] offer evi-
dence to strengthen inference from existing observational
and RCT studies and to inform future research. The term
‘genocopy’ refers to genetic variation that generates an
outcome similar to that produced by an environmental
exposure [7]. An illustrative example of this phenomenon
is the autosomal recessive condition of Hartnup disease.
This disease is caused by a mutation in solute carrier fam-
ily 6 member 19 (SLC6A19; the ‘genocopy’) but a very
similar clinical manifestation occurs in cases of dietary
niacin deficiency, a condition known as pellagra (the
‘phenocopy’). Using a Mendelian randomization approach
that takes advantage of the properties of genetic variation
and follows similar logic (such that mutations in NCP1L1
act as genocopies mimicking the action of ezetimibe),
Stitziel et al. [6] attempt to separate causation from asso-
ciation, providing validation of NCP1L1 as a therapeutic
target.
Using human genetics to validate the role of
NCP1L1 in coronary heart disease
Using sequence data from over 22,000 individuals of
varying ancestry, Stitziel and colleagues [6] identify 15
mutations that are predicted to inactivate NCP1L1. The
mutations lie within one of the gene’s 20 protein-coding
exons and, for the researchers to consider them as inacti-
vating, they had to be classified as nonsense, splice-site or
frameshift mutations. The variants identified are rare, be-
ing found in only around 1 in 650 participants, and exist-
ing only in a heterozygous state. The most frequently
observed mutation was p.Arg406X, which had a minor al-
lele frequency of 0.02% among participants of European
ancestry. Stitziel and co-workers [6] went on to genotype
this variant in a further nine independent sample sets,
totalling 91,002 participants. This targeted genotyping
afforded the study a considerable gain in statistical power,
increasing the number of participants carrying an inacti-
vating variant from 34 in 22,092 to 82 in 113,094.
Data obtained for all the participants in the study in-
cluded medical history and laboratory assessments for car-
diovascular risk factors. These data were combined with
the genetic data, firstly to test the association between
NCP1L1 protein-activating mutations and plasma lipid
levels, and subsequently to test for an association between
these same mutations and risk of CHD. Association
analyses revealed that carriers of any of the NCP1L1
inactivating mutations identified had lower levels of
total cholesterol, LDL-C and triglycerides. In an analysis
that was restricted to participants characterized as being
free from CHD, the mean LDL-C level was 12 mg per
decilitre lower in carriers of an inactivating mutation than
in non-carriers, while no difference was observed in high-
density lipoprotein cholesterol.
Having used the clinical data available for each study
to define CHD status, Stitziel et al. [6] went on to dem-
onstrate an odds ratio for the disease among carriers of
inactivating mutations of 0.47 (95% confidence interval,
0.25 to 0.87). The odds ratio was calculated based on
carrier frequencies of 0.04% in 29,954 patients with CHD
compared with frequencies of 0.09% in 83,140 unaffected
participants. The apparent protective effect of NCP1L1
protein-inactivating mutations against high plasma lipid
levels and CHD observed in the entire cohort was also
evident when the analysis was conducted separately in
European and African subgroups.
Clinical interpretation
By using naturally occurring genetic variants, Stitziel and
colleagues [6] exploit a natural experiment that simulates
the effect of exposure to ezetimibe and avoids many of the
pitfalls associated with traditional observational studies.
Of course, when interpreting the results of such studies it
is important to take into consideration (as Stitziel and co-
workers [6] do) that genetic models, such as this one for
NCP1L1 inactivation, are not a perfect proxy for pharma-
cologic therapy. For example, one important caveat is that
the drug could have off-target effects that may not be
modelled in the case of a single-gene framework. How-
ever, when it comes to modelling the long-term effects
of treatment, such Mendelian randomization-style ap-
proaches are well placed to detect life course effects.
Genetic variation can provide a natural life course
model because it represents lifetime exposure to the
effects of mutation, which in this case mirrors the ac-
tion of ezetimibe [8,9].
The use of genetic variation to assess drug effects is an
established approach and the identification of novel rare
variants of large effect adds to its potential. Whether the
use of such variants provides benefits over and above
those seen using common variants is unclear, but it is
possible that the resultant genetic model is one that
more closely resembles the drug effect being simulated
and has greater power to detect differences in disease
risk because of the relatively large effect sizes observed.
Whether or not this is the case will likely become clearer
as more studies are published, with some insight already
having been provided in a similar study in which multiple
mutations in NCP1L1 and HMGCR were considered in
concert using a genetic score approach to explore the im-
pact of combination therapy with statins and ezetimibe on
CHD risk [10]. There are many situations in which the
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approach taken by Stitziel et al. [6] could be utilized,
but one particularly important application might be in
providing validation of proposed therapeutic targets
before the clinical trial stage.
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